Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662896 · ClinicalTrials.gov registry record · Phase 1
To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension
A Phase 1 study, sponsored by NicOx.
- Completed
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
NCT00662896 is a Phase 1 study that has completed, run by NicOx. The registered enrollment target is 300 participants.
The verdict
NCT00662896, a Phase 1 study, has completed, sponsored by NicOx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
Study Summary
To assess the effect of naproxcinod vs. naproxen and ibuprofen on arterial blood pressure in patients with osteoarthritis and controlled essential hypertension
Interventions
- DRUG naproxcinod 375 mg bid
- DRUG naproxcinod 750 mg bid
- DRUG naproxen 250 mg bid
- DRUG naproxen 500 mg bid
- DRUG ibuprofen 600 mg tid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662896
The ClinicalTrials.gov registry entry for NCT00662896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NicOx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which naproxcinod 375 mg bid is the first listed.
NCT00662896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662896 about?
NCT00662896 is a clinical study titled "To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension". To assess the effect of naproxcinod vs. naproxen and ibuprofen on arterial blood pressure in patients with osteoarthritis and controlled essential hypertension
What is the current status of trial NCT00662896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2008-03. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00662896?
The interventions under investigation include: naproxcinod 375 mg bid (DRUG), naproxcinod 750 mg bid (DRUG), naproxen 250 mg bid (DRUG), naproxen 500 mg bid (DRUG), ibuprofen 600 mg tid (DRUG).
Who is sponsoring clinical trial NCT00662896?
This trial is sponsored by NicOx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.